Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease
VE Torres, X Wang, Q Qian, S Somlo, PC Harris… - Nature medicine, 2004 - nature.com
VE Torres, X Wang, Q Qian, S Somlo, PC Harris, VH Gattone
Nature medicine, 2004•nature.comAutosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage
renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been
effective in two animal models of PKD with pathologies that are probably related. Here we
show, in a mouse model of ADPKD (Pkd2−/tm1Som), a similar cellular phenotype and
response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels,
prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal …
renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been
effective in two animal models of PKD with pathologies that are probably related. Here we
show, in a mouse model of ADPKD (Pkd2−/tm1Som), a similar cellular phenotype and
response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels,
prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal …
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2−/tm1Som), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.
nature.com